Merck lays out subcutaneous Keytruda data in lung cancer amid patent brawl with Halozyme
27th March 2025 Uncategorised 0Merck & Co.’s subcutaneous formulation of Keytruda has matched up to the original intravenous version on two blood concentration measurements, paving way for a potential FDA approval that could give patients a more convenient option of the widely used cancer drug.
More: Merck lays out subcutaneous Keytruda data in lung cancer amid patent brawl with Halozyme
Source: fierce